LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Rhea-AI Summary

LakeShore Biopharma (Nasdaq: LSB) announced financial results for Fiscal Year 2024, ending March 31, 2024. Despite revenue challenges due to supply chain issues, the company reported:

- Revenue of RMB573.4 million (US$80.8 million), down 16.6% year-over-year
- Gross profit of RMB455.7 million (US$64.2 million)
- Gross margin increased to 79.5%, up 1.8 percentage points
- Net loss of RMB433.5 million (US$61.1 million)

LakeShore Biopharma maintains its position as a leading rabies vaccine producer in China, having sold over 27.3 million doses since October 2020. The company's pipeline continues to advance, with positive interim results from the PIKA rabies vaccine Phase III trial. For Fiscal Year 2025, LakeShore anticipates double-digit revenue growth and expects to achieve breakeven.

Positive

• Gross margin increased to 79.5%, up 1.8 percentage points from previous year
• Maintained position as one of the top rabies vaccine producers in China
• Positive interim results from Phase III trial of PIKA rabies vaccine
• Anticipates double-digit year-over-year revenue growth for Fiscal Year 2025
• Expects to achieve breakeven in Fiscal Year 2025

Negative

• Revenue decreased 16.6% year-over-year to RMB573.4 million (US$80.8 million)
• Net loss increased to RMB433.5 million (US$61.1 million) from RMB145.5 million in previous year
• Impairment loss on inventory, PP&E, and other assets increased to RMB157.4 million (US$22.2 million)
• Cash and cash equivalents decreased to RMB246.6 million (US$34.7 million) from RMB370.4 million

Financial Analyst

LakeShore Biopharma's FY2024 results present a mixed financial picture. While revenue declined 16.6% to RMB573.4 million, gross margin improved to 79.5%. The company's net loss widened to RMB433.5 million, primarily due to increased expenses and impairment losses.

Looking ahead, management's projection of double-digit revenue growth and breakeven for FY2025 is ambitious given current challenges. The resolution of inventory issues and operational improvements are positive, but the company needs to demonstrate consistent execution. Investors should closely monitor the company's ability to control costs and drive top-line growth in the coming quarters.

Medical Research Analyst

LakeShore Biopharma's pipeline progress is promising, particularly the positive interim results from the Phase III trial of their PIKA rabies vaccine. The potential for a one-week regimen could be a game-changer in rabies prevention. The advancement of PIKA YS-ON-001 for cancer immunotherapy and YS-HBV-002 for chronic hepatitis B also demonstrates a diverse and innovative portfolio.

However, investors should note that clinical success doesn't guarantee commercial viability. The company's ability to navigate regulatory approvals and successfully commercialize these products will be important for long-term growth. The focus on rabies vaccines in China provides a stable base, but expansion into new therapeutic areas and markets will be key for future success.

Gross margin increased to 79.5%; product pipeline continues to advance

Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025

GAITHERSBURG, Md., Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the fiscal year ended March 31, 2024 ("Fiscal Year 2024").

Mr. Dave Chenn, Chairman and Interim Chief Executive Officer of the Company, commented, "In Fiscal Year 2024, our revenue was affected by a shortage of finished product inventory, resulting from earlier supply chain disruptions at our YSJA rabies vaccine production facilities. Despite these difficulties, we have successfully implemented operational improvements that have normalized production, and our inventory challenges are now resolved as we enter Fiscal Year 2025. We have maintained our position as a leading rabies vaccine producer in China, and continued to improve our gross margin by emphasizing operational efficiency. We also made significant advancements in our product pipeline during Fiscal Year 2024, progressing our next-generation PIKA rabies vaccine through its ongoing Phase III clinical trial and meeting significant developmental milestones for other pipeline products."

Mr. Dave Chenn continued, "Looking ahead, our Fiscal Year 2025 strategy will focus on driving revenue growth, controlling expenses, and enhancing profit margins. We are implementing a comprehensive plan that includes cost reductions, organizational restructuring, strengthened internal controls, and strategic resource allocation to key growth areas. Our goal will be to foster innovation, efficiency, stability, and sustainable profitability as we work to build value for our shareholders."

Ms. Rachel Yu, Interim Chief Financial Officer of the Company, added, "For Fiscal Year 2024, we recorded revenues of RMB573.4 million (US$80.8 million), representing a decrease compared to Fiscal Year 2023 due to persistent supply chain issues affecting raw material availability, manufacturing processes, and overall output capacity which impacted our topline. We recorded a gross profit of RMB455.7 million (US$64.2 million), and our gross margin increased by 1.8 percentage points to 79.5% compared to Fiscal Year 2023. With cash and cash equivalents of RMB246.6 million (US$34.7 million), we will maintain our focus on maximizing long-term shareholder returns by refining our business strategies and leveraging new market opportunities. Looking ahead to Fiscal Year 2025, we anticipate double-digit year-over-year growth in revenues, and expect to achieve breakeven on our bottom line by the time our fiscal year concludes on March 31, 2025."

Business Updates

YSJA^TM Rabies Vaccine

LakeShore Biopharma's marketed vaccine product, YSJA^TM rabies vaccine, is the first aluminum-free lyophilized rabies vaccine launched in China. Since the Company commenced production at its current GMP-compliant facilities in February 2020, and commercialization of the product in late 2020, market intake of the Company's YSJA rabies vaccine has been consistent and strong. As of March 31, 2024, LakeShore Biopharma maintained its leadership position as one of the top rabies vaccine producers in China and has sold more than 27.3 million doses of YSJA^TM rabies vaccines to approximately 1,767 Chinese Center(s) for Disease Control and Prevention ("CDC") customers, which represents 61.3% of CDC customers in China since October 2020.

Clinical Pipeline

LakeShore Biopharma continues to prioritize and advance its portfolio of innovative product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA YS-ON-001, and PIKA YS-HBV-002.

PIKA Rabies Vaccine

• In April 2024, the Company announced positive interim results from the ongoing Phase III clinical trial of its next-generation PIKA rabies vaccine in the Philippines and Pakistan. The interim results indicate that the PIKA rabies vaccine has successfully met the primary endpoints of the trial and has the potential to achieve best-in-class accelerated protection and meet the World Health Organization's goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens. Subject to successful completion of the Phase III clinical trial, the Company plans to submit the New Drug Applications/Biologics License Applications to relevant regulatory authorities throughout Asia, Africa, Europe, and the Americas.

PIKA YS-ON-001

• PIKA YS-ON-001 is designed as an immunological therapeutical agent against cancers. In 2023, the Company completed the Phase I clinical trial of PIKA YS-ON-001 in China.

PIKA YS-HBV-002

• In April 2024, the Company announced that its YS-HBV-002, the second generation of immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus infection, had been granted clinical trial approval by the Philippine Food and Drug Administration. In light of the approval, the Company is preparing to initiate a Phase I clinical trial for YS-HBV-002 in the Philippines.

Fiscal Year 2024 Financial Results

Total Revenue

Total revenue was RMB573.4 million (US$80.8 million) in Fiscal Year 2024, compared to RMB687.2 million in the same period of 2023, representing a decrease of 16.6%. This was primarily due to COVID-related disruptions affecting the Company's manufacturing operations and production, which reduced batch approvals and doses available for sale. This impact was partially offset by an increase in the product price of the YSJA rabies vaccine of approximately RMB2.9 per dose.

Gross Profit

Gross profit in Fiscal Year 2024 was RMB455.7 million (US$64.2 million), representing a 79.5% gross margin, compared to RMB533.8 million, or a 77.7% gross margin, in the same period of 2023. The improvement in gross margin was primarily due to the increase in unit price of the YSJA rabies vaccine, and a decrease in unit cost resulting from lowered delivery costs and an increase in production batches.

Selling and Marketing Expenses

Selling and marketing expenses in Fiscal Year 2024 were RMB301.3 million (US$42.5 million), compared to RMB272.9 million in the same period of 2023. This change was primarily due to an increase in promoting and marketing service fees to continuously promote the YSJA rabies vaccine.

General and Administrative Expenses

General and administrative expenses in Fiscal Year 2024 were RMB140.1 million (US$19.7 million), compared to RMB72.9 million in the same period of 2023. This change was primarily attributable to increases in legal fees, auditing fees, directors & officers liability insurance costs, and employee benefits.

Research and Development Expenses

Research and development expenses in Fiscal Year 2024 were RMB302.8 million (US$42.7 million), compared to RMB318.7 million in the same period of 2023. The change was primarily driven by decreases in testing fees, clinical trial fees, and consulting service fees related to the development of the Company's COVID-19 vaccine, and decreases in employee benefits as a result of staffing optimizations.

Impairment Loss on Inventory, Property, Plant and Equipment, and Other Assets

Impairment loss on inventory, property, plant and equipment ("PP&E"), and other assets in Fiscal Year 2024 was RMB157.4 million (US$22.2 million), compared to RMB8.7 million in the same period of 2023. The change was primarily attributable to 1) impairment loss on inventory impacted by COVID-related disruptions affecting the Company's manufacturing operations and production and raw materials used in the research and development of the Company's COVID-19 vaccine, and 2) impairment loss on PP&E related to COVID-19 vaccine equipment.

Net Loss

Net loss for Fiscal Year 2024 was RMB433.5 million (US$61.1 million), compared with RMB145.5 million in the same period of 2023.

Balance Sheet

As of March 31, 2024, the Company had cash and cash equivalents of RMB246.6 million (US$34.7 million), compared with RMB370.4 million as of March 31, 2023.

Business Outlook

The Company anticipates double-digit year-over-year revenue growth and expects to achieve breakeven in Fiscal Year 2025.

The above outlook is based on information available as of the date of this press release and reflects the Company's current and preliminary expectations regarding its business situation and market conditions. The outlook is subject to changes, especially given uncertainties and situations related to market competitive dynamics and regulatory policies, etc.

About LakeShore Biopharma 

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit https://investor.lakeshorebio.com/.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.095 to US$1.00, the exchange rate set forth in the central parity rate release of the People's Bank of China on March 31, 2024.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma's ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the company's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Investor Relations Contact

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com 

 

 

LAKESHORE BIOPHARMA CO., LTD AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET (AUDITED)
		As of March 31,
		2023				2024				2024
		(RMB)				(RMB)				(US$)
ASSETS
Current assets
Cash			370,108,059				246,351,231			$	34,721,808
Restricted cash			261,766				200,000				28,189
Accounts receivable, net			463,051,792				444,161,291				62,602,014
Advance to suppliers, net			6,763,326				1,662,739				234,354
Inventories, net			185,380,952				203,422,602				28,671,262
Prepaid expenses and other current assets			10,412,769				7,370,089				1,038,772
Total current assets			1,035,978,664				903,167,952				127,296,399
Non-current assets
Property, plant and equipment, net			571,756,443				473,348,006				66,715,716
Operating lease right-of-use assets, net			11,132,428				7,275,367				1,025,422
Deferred tax assets, net			1,905,581				23,634,189				3,331,105
Intangible assets, net			78,056,792				71,245,336				10,041,626
Other assets, non-current			20,923,703				34,356,506				4,842,355
Total non-current assets			683,774,947				609,859,404				85,956,224
Total assets			1,719,753,611				1,513,027,356			$	213,252,623
LIABILITIES AND SHAREHOLDERS'    (DEFICIT)/EQUITY
Current liabilities
Bank loans and other borrowings - current			193,736,563				318,540,732			$	44,896,509
Accounts payable			80,439,489				67,774,798				9,552,473
Accrued expenses and other liabilities			377,536,644				408,737,969				57,609,301
Operating lease liabilities - current			4,753,547				5,156,540				726,785
Deferred government grants - current			2,295,701				2,015,693				284,100
Total current liabilities			658,761,944				802,225,732				113,069,168
Non-current liabilities
Bank loans and other borrowings – non-current			293,790,596				98,983,780				13,951,202
Operating lease liabilities - non-current			6,348,890				1,783,593				251,387
Deferred government grants - non-current			23,606,507				20,279,945				2,858,343
Warrants liability			8,792,389				4,548,004				641,015
Total non-current liabilities			332,538,382				125,595,322				17,701,947
Total liabilities			991,300,326				927,821,054				130,771,115
Shareholders'(deficit)/equity
Ordinary shares, par value US$0.00002 per share;          9,950,000,000 shares authorized; 93,058,197 and          190,227,959 shares issued and outstanding as of March 31,          2023 and 2024, respectively *			12,297				26,105				3,679
Additional paid-in capital			2,656,891,036				2,950,862,914				415,907,387
Accumulated deficit			(1,874,037,965)				(2,307,502,836)				(325,229,434)
Accumulated other comprehensive loss			(54,412,083)				(58,179,881)				(8,200,124)
Total shareholders' equity			728,453,285				585,206,302				82,481,508
Total liabilities and shareholders' equity			1,719,753,611				1,513,027,356			$	213,252,623
* Gives retroactive effect to the business combination in March 2023

 

 

LAKESHORE BIOPHARMA CO., LTD AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (AUDITED)
		Years Ended March 31,
			2023				2024				2024
			(RMB)				(RMB)				(US$)
Revenues				687,201,070				573,418,256			$	80,820,050
Cost of revenues				153,360,262				117,688,301				16,587,498
Gross profit				533,840,808				455,729,955				64,232,552
Operating expenses:
Selling and marketing				272,927,356				301,259,528				42,460,821
General and administrative				72,939,790				140,086,062				19,744,336
Impairment loss on inventory, property, plant          and equipment and other assets				8,655,487				157,415,875				22,186,875
Research and development				318,700,526				302,800,992				42,678,082
Total operating expenses				673,223,159				901,562,457				127,070,114
Loss from operations				(139,382,351)				(445,832,502)				(62,837,562)
Other income (expenses):
Late fees for taxes other than income tax				(3,603)				-				-
Late fees for social security insurance				(747,609)				(756,201)				(106,582)
Government grants				26,072,517				20,708,778				2,918,785
Financial expenses, net				(30,857,673)				(44,344,808)				(6,250,149)
Fair value changes of warrant liability				21,358				4,458,844				628,449
Other (expense) income, net				551,760				10,572,411				1,490,121
Total other income (expense), net				(4,963,250)				(9,360,976)				(1,319,376)
Loss before income taxes				(144,345,601)				(455,193,478)				(64,156,938)
Income tax (expense) benefit				(1,133,504)				21,728,607				3,062,524
Net loss				(145,479,105)				(433,464,871)				(61,094,414)
Accretion to redemption value of convertible            redeemable preferred shares				(137,991,697)				-				-
Net loss attributable to Lakeshore Group				(283,470,802)				(433,464,871)			$	(61,094,414)
Net loss				(145,479,105)				(433,464,871)			$	(61,094,414)
Other comprehensive income (loss): foreign          currency translation adjustment				(137,500,063)				(3,767,798)				(531,050)
Total comprehensive loss				(282,979,168)				(437,232,669)			$	(61,625,464)
Loss per share*:
– Basic and Diluted				(2.35)				(4.05)			$	(0.57)
Weighted average number of ordinary shares     outstanding*:
– Basic and Diluted				61,785,466				106,923,121				106,923,121
* Gives retroactive effect to the business combination in March 2023.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-financial-results-for-fiscal-year-2024-302223505.html

SOURCE LakeShore Biopharma Co., Ltd

FAQ

What was LakeShore Biopharma's revenue for Fiscal Year 2024?

LakeShore Biopharma's revenue for Fiscal Year 2024 was RMB573.4 million (US$80.8 million), representing a 16.6% decrease compared to Fiscal Year 2023.

How many doses of YSJA rabies vaccine has LakeShore Biopharma sold since October 2020?

LakeShore Biopharma has sold more than 27.3 million doses of YSJA rabies vaccines to approximately 1,767 Chinese Center(s) for Disease Control and Prevention customers since October 2020.

What is LakeShore Biopharma's financial outlook for Fiscal Year 2025?

For Fiscal Year 2025, LakeShore Biopharma anticipates double-digit year-over-year revenue growth and expects to achieve breakeven on its bottom line.

What were the interim results of the PIKA rabies vaccine Phase III trial?

LakeShore Biopharma announced positive interim results from the ongoing Phase III clinical trial of its PIKA rabies vaccine, indicating that it has successfully met the primary endpoints of the trial.